ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Clinical trials for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) explained in plain language.
Never miss a new study
Get alerted when new ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) trials appear
Sign up with your email to follow new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a lower aspirin dose be safer for elderly heart patients?
Disease control Recruiting nowThis study looks at whether a lower dose of aspirin (50 mg daily) works as well as the standard dose (100 mg) to prevent heart attacks and strokes in people aged 60 and older with heart disease. It involves over 5,400 Chinese participants who will be followed for about 6 years. T…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Sponsor: Peking University First Hospital • Aim: Disease control
Last updated May 17, 2026 14:27 UTC
-
Could a simple pill combo slash heart attacks and strokes?
Disease control Recruiting nowThis study tests whether a daily polypill (combining several heart medications) plus colchicine can reduce major heart problems like heart attacks, strokes, and amputations in people with established heart or artery disease. About 7,700 to 10,800 adults aged 45 and older with a h…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Phase: PHASE3 • Sponsor: Hospital do Coracao • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug targets hidden heart risk factor in 340 patients
Disease control Recruiting nowThis study tests a new medicine called pelacarsen in people with heart disease who have high levels of a blood fat called Lp(a), which increases heart attack risk. Participants will also receive another cholesterol-lowering drug, inclisiran. The goal is to see if pelacarsen can s…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug aims to cut heart attacks in people with hidden cholesterol risk
Disease control Recruiting nowThis study tests a drug called muvalaplin in about 10,450 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease and stroke. Participants either have had a prior heart attack, stroke, or artery procedure, or are at high risk for a first event. The goal…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
New study aims to catch heart disease early in rheumatoid arthritis patients
Knowledge-focused Recruiting nowThis study is for adults aged 40-79 with rheumatoid arthritis who have at least one heart disease risk factor (like high blood pressure or smoking). Researchers want to see if a heart scan and a blood test can find early signs of heart trouble before symptoms appear. The goal is …
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated May 17, 2026 14:30 UTC
-
Heart scan study targets hidden danger in inherited high cholesterol patients
Knowledge-focused Recruiting nowThis study aims to find how common hidden heart artery blockages are in people with familial hypercholesterolemia (inherited high cholesterol) who have no symptoms. Researchers will use a special CT scan to look for significant blockages in 600 participants. The goal is to better…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Phase: NA • Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC